Langwirksame medikamente zur behandlung der hyperkinetischen störungen.: Eine systematische übersicht und europäische behandlungsleitlinien.Teil 2: Ein quantitativer Vergleich der langwirksamen Präparate

Tobias Banaschewski; D. Coghill; Paramala Santosh; Aleassandro Zuddas; Philip Asherson; Jan Buitelaar; Marina Danckaerts; Manfred Döpfner; Stephen V. Faraone; Aribert Rothenberger; Joseph Sergeant; Hans-Christoph Steinhausen; Edmund J.S. Sonuga-Barke; Eric Taylor

doi:10.1024/1422-4917.36.2.97

Langwirksame medikamente zur behandlung der hyperkinetischen störungen. Eine systematische übersicht und europäische behandlungsleitlinien.Teil 2: Ein quantitativer Vergleich der langwirksamen Präparate

Translated title of the contribution: Long-acting medications for the treatment of hyperkinetic disorders: A systematic review and European treatment guideline. Part 2: A quantitative evaluation of long-acting medications

Tobias Banaschewski (Lead / Corresponding author), D. Coghill, Paramala Santosh, Aleassandro Zuddas, Philip Asherson, Jan Buitelaar, Marina Danckaerts, Manfred Döpfner, Stephen V. Faraone, Aribert Rothenberger, Joseph Sergeant, Hans-Christoph Steinhausen, Edmund J.S. Sonuga-Barke, Eric Taylor

Research output: Contribution to journal › Article › peer-review

11 Citations (Scopus)

Abstract

A panel of experts from several European countries has accomplished a systematic review of published and unpublished data on the use of long-acting medications in ADHD and hyperkinetic disorder. Based on this analysis detailed recommendations about the use of these drugs in practice have been developed: (1) Long-acting preparations should be licensed and used; (2) They should not completely replace short-acting drugs (which will be the initial treatment for many children in view of cost and the greater flexibility of dosing). Individual clinical choices are necessary. (3) Both ATX and extended-release stimulants should be available. In addition, detailed recommendations will be made with regard to the criteria to be applied in choosing a preparation for the individual patient. © 2008 by Verlag Hans Huber, Hogrefe AG.

Translated title of the contribution	Long-acting medications for the treatment of hyperkinetic disorders: A systematic review and European treatment guideline. Part 2: A quantitative evaluation of long-acting medications
Original language	German
Pages (from-to)	97-107
Number of pages	11
Journal	Zeitschrift fur Kinder-und Jugendpsychiatrie und Psychotherapie
Volume	36
Issue number	2
DOIs	https://doi.org/10.1024/1422-4917.36.2.97
Publication status	Published - 1 Mar 2008

Keywords

Guidelines
Review
Stimulants
Atomoxetine
ADHD

Access to Document

10.1024/1422-4917.36.2.97

Cite this

Banaschewski, T., Coghill, D., Santosh, P., Zuddas, A., Asherson, P., Buitelaar, J., Danckaerts, M., Döpfner, M., Faraone, S. V., Rothenberger, A., Sergeant, J., Steinhausen, H.-C., Sonuga-Barke, E. J. S., & Taylor, E. (2008). Langwirksame medikamente zur behandlung der hyperkinetischen störungen. Eine systematische übersicht und europäische behandlungsleitlinien.Teil 2: Ein quantitativer Vergleich der langwirksamen Präparate. Zeitschrift fur Kinder-und Jugendpsychiatrie und Psychotherapie, 36(2), 97-107. https://doi.org/10.1024/1422-4917.36.2.97

Banaschewski, Tobias ; Coghill, D. ; Santosh, Paramala et al. / Langwirksame medikamente zur behandlung der hyperkinetischen störungen. Eine systematische übersicht und europäische behandlungsleitlinien.Teil 2: Ein quantitativer Vergleich der langwirksamen Präparate. In: Zeitschrift fur Kinder-und Jugendpsychiatrie und Psychotherapie. 2008 ; Vol. 36, No. 2. pp. 97-107.

@article{e30a9680422b43be9d72db00e3902703,

title = "Langwirksame medikamente zur behandlung der hyperkinetischen st{\"o}rungen.: Eine systematische {\"u}bersicht und europ{\"a}ische behandlungsleitlinien.Teil 2: Ein quantitativer Vergleich der langwirksamen Pr{\"a}parate",

abstract = "A panel of experts from several European countries has accomplished a systematic review of published and unpublished data on the use of long-acting medications in ADHD and hyperkinetic disorder. Based on this analysis detailed recommendations about the use of these drugs in practice have been developed: (1) Long-acting preparations should be licensed and used; (2) They should not completely replace short-acting drugs (which will be the initial treatment for many children in view of cost and the greater flexibility of dosing). Individual clinical choices are necessary. (3) Both ATX and extended-release stimulants should be available. In addition, detailed recommendations will be made with regard to the criteria to be applied in choosing a preparation for the individual patient. {\textcopyright} 2008 by Verlag Hans Huber, Hogrefe AG.",

keywords = "Guidelines, Review, Stimulants , Atomoxetine, ADHD",

author = "Tobias Banaschewski and D. Coghill and Paramala Santosh and Aleassandro Zuddas and Philip Asherson and Jan Buitelaar and Marina Danckaerts and Manfred D{\"o}pfner and Faraone, {Stephen V.} and Aribert Rothenberger and Joseph Sergeant and Hans-Christoph Steinhausen and Sonuga-Barke, {Edmund J.S.} and Eric Taylor",

note = "MEDLINE{\textregistered} is the source for the MeSH terms of this document.",

year = "2008",

month = mar,

day = "1",

doi = "10.1024/1422-4917.36.2.97",

language = "German",

volume = "36",

pages = "97--107",

journal = "Zeitschrift fur Kinder-und Jugendpsychiatrie und Psychotherapie",

issn = "1422-4917",

publisher = "Hogrefe Publishing Corp.",

number = "2",

}

Banaschewski, T, Coghill, D, Santosh, P, Zuddas, A, Asherson, P, Buitelaar, J, Danckaerts, M, Döpfner, M, Faraone, SV, Rothenberger, A, Sergeant, J, Steinhausen, H-C, Sonuga-Barke, EJS & Taylor, E 2008, 'Langwirksame medikamente zur behandlung der hyperkinetischen störungen. Eine systematische übersicht und europäische behandlungsleitlinien.Teil 2: Ein quantitativer Vergleich der langwirksamen Präparate', Zeitschrift fur Kinder-und Jugendpsychiatrie und Psychotherapie, vol. 36, no. 2, pp. 97-107. https://doi.org/10.1024/1422-4917.36.2.97

Langwirksame medikamente zur behandlung der hyperkinetischen störungen. Eine systematische übersicht und europäische behandlungsleitlinien.Teil 2: Ein quantitativer Vergleich der langwirksamen Präparate. / Banaschewski, Tobias (Lead / Corresponding author); Coghill, D.; Santosh, Paramala et al.
In: Zeitschrift fur Kinder-und Jugendpsychiatrie und Psychotherapie, Vol. 36, No. 2, 01.03.2008, p. 97-107.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Langwirksame medikamente zur behandlung der hyperkinetischen störungen.

T2 - Eine systematische übersicht und europäische behandlungsleitlinien.Teil 2: Ein quantitativer Vergleich der langwirksamen Präparate

AU - Banaschewski, Tobias

AU - Coghill, D.

AU - Santosh, Paramala

AU - Zuddas, Aleassandro

AU - Asherson, Philip

AU - Buitelaar, Jan

AU - Danckaerts, Marina

AU - Döpfner, Manfred

AU - Faraone, Stephen V.

AU - Rothenberger, Aribert

AU - Sergeant, Joseph

AU - Steinhausen, Hans-Christoph

AU - Sonuga-Barke, Edmund J.S.

AU - Taylor, Eric

N1 - MEDLINE® is the source for the MeSH terms of this document.

PY - 2008/3/1

Y1 - 2008/3/1

N2 - A panel of experts from several European countries has accomplished a systematic review of published and unpublished data on the use of long-acting medications in ADHD and hyperkinetic disorder. Based on this analysis detailed recommendations about the use of these drugs in practice have been developed: (1) Long-acting preparations should be licensed and used; (2) They should not completely replace short-acting drugs (which will be the initial treatment for many children in view of cost and the greater flexibility of dosing). Individual clinical choices are necessary. (3) Both ATX and extended-release stimulants should be available. In addition, detailed recommendations will be made with regard to the criteria to be applied in choosing a preparation for the individual patient. © 2008 by Verlag Hans Huber, Hogrefe AG.

AB - A panel of experts from several European countries has accomplished a systematic review of published and unpublished data on the use of long-acting medications in ADHD and hyperkinetic disorder. Based on this analysis detailed recommendations about the use of these drugs in practice have been developed: (1) Long-acting preparations should be licensed and used; (2) They should not completely replace short-acting drugs (which will be the initial treatment for many children in view of cost and the greater flexibility of dosing). Individual clinical choices are necessary. (3) Both ATX and extended-release stimulants should be available. In addition, detailed recommendations will be made with regard to the criteria to be applied in choosing a preparation for the individual patient. © 2008 by Verlag Hans Huber, Hogrefe AG.

KW - Guidelines

KW - Review

KW - Stimulants

KW - Atomoxetine

KW - ADHD

UR - http://www.scopus.com/inward/record.url?scp=41749083730&partnerID=8YFLogxK

U2 - 10.1024/1422-4917.36.2.97

DO - 10.1024/1422-4917.36.2.97

M3 - Article

SN - 1422-4917

VL - 36

SP - 97

EP - 107

JO - Zeitschrift fur Kinder-und Jugendpsychiatrie und Psychotherapie

JF - Zeitschrift fur Kinder-und Jugendpsychiatrie und Psychotherapie

IS - 2

ER -

Banaschewski T, Coghill D, Santosh P, Zuddas A, Asherson P, Buitelaar J et al. Langwirksame medikamente zur behandlung der hyperkinetischen störungen. Eine systematische übersicht und europäische behandlungsleitlinien.Teil 2: Ein quantitativer Vergleich der langwirksamen Präparate. Zeitschrift fur Kinder-und Jugendpsychiatrie und Psychotherapie. 2008 Mar 1;36(2):97-107. doi: 10.1024/1422-4917.36.2.97

Langwirksame medikamente zur behandlung der hyperkinetischen störungen. Eine systematische übersicht und europäische behandlungsleitlinien.Teil 2: Ein quantitativer Vergleich der langwirksamen Präparate

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this